| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL.
Correspondence to: Henry Wagner, Jr, MD, H. Lee Moffit Cancer Center and Research Institute, 12902 Magnolia Dr, Room 3157, Tampa, FL 33612-9497; e-mail: Decomarj{at}moffitt.usf.edu
Patients with clinical stage I and II non-small cell lung cancer (NSCLC) generally are considered candidates for surgical resection, with cure rates as high as 80% reported for some subsets. Locoregional and systemic adjuvant therapies have been evaluated in patients with lymph node involvement or pathologic T3 status, although considerable controversy regarding an appropriate standard of care continues to exist. Several trials have evaluated postoperative radiation therapy, the majority of which suggest that overall survival may be only minimally improved with this adjuvant therapy, but local failure is probably reduced. Trials evaluating the role of adjuvant chemotherapy have been few, often enrolling small numbers of patients. Several recent reviews summarizing the results of these trials suggest that, although some adjuvant chemotherapy regimens may have biological activity, results have not been consistent, and further study is warranted for regimens that include newer chemotherapy agents. CNS relapse is one of the most common sites of metastasis in NSCLC, and prophylactic cranial irradiation (PCI) has been evaluated in a number of trials to reduce the risk of local failure at this site. Data from these trials strongly suggest that a prospective trial of PCI in patients with NSCLC at high risk for isolated CNS relapse is warranted. Future clinical trials evaluating new radiographic, immunologic, and molecular technologies for early detection of second primary tumors also should be considered, particularly in patients with resected T1N0M0 lesions.
This article has been cited by other articles:
|
|
 |
|
  J. H. Park, C.-T. Lee, H. W. Lee, H. J. Baek, J. I. Zo, and Y. M. Shim Postoperative adjuvant chemotherapy for stage I non-small cell lung cancer Eur. J. Cardiothorac. Surg., June 1, 2005; 27(6): 1086 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Marra and G. Stamatis Reply to the editor J. Thorac. Cardiovasc. Surg., November 1, 2003; 126(5): 1665 - 1666. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Alexiou, D. Beggs, P. Onyeaka, K. Kotidis, S. Ghosh, L. Beggs, D. N. Hopkinson, J. P. Duffy, W. E. Morgan, and G. Rocco Pneumonectomy for Stage I (T1N0 and T2N0) nonsmall cell lung cancer has potent, adverse impact on survival Ann. Thorac. Surg., October 1, 2003; 76(4): 1023 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Marra, L. Hillejan, G. Zaboura, T. Fujimoto, D. Greschuchna, and G. Stamatis Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis J. Thorac. Cardiovasc. Surg., March 1, 2003; 125(3): 543 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Rena, A. Oliaro, A. Cavallo, P. L. Filosso, G. Donati, P. Di Marzio, G. Maggi, and E. Ruffini Stage I non-small cell lung carcinoma: really an early stage? Eur. J. Cardiothorac. Surg., March 1, 2002; 21(3): 514 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Machtay, J. H. Lee, J. B. Shrager, L. R. Kaiser, and E. Glatstein Risk of Death From Intercurrent Disease Is Not Excessively Increased by Modern Postoperative Radiotherapy for High-Risk Resected Non-Small-Cell Lung Carcinoma J. Clin. Oncol., October 1, 2001; 19(19): 3912 - 3917. [Abstract] [Full Text]
|
|
|
|
|
|
T. C. Mineo, V. Ambrogi, V. Corsaro, and M. Roselli Postoperative adjuvant therapy for stage IB non-small-cell lung cancer Eur. J. Cardiothorac. Surg., August 1, 2001; 20(2): 378 - 384. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
